Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Zydus (Details)

v3.20.1
Licensing and Other Arrangements - Zydus (Details)
$ in Thousands
3 Months Ended
Mar. 03, 2020
USD ($)
item
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Licensing and other arrangements      
Revenue from contracts with customers   $ 500 $ 8,026
Zydus | License Agreement      
Licensing and other arrangements      
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events $ 500    
Maximum amount receivable upon achievement of commercial milestones $ 23,500    
Number of performance obligations | item 1    
Contract assets   0  
Contract liabilities   0  
Capitalized contract costs   0  
Revenue from contracts with customers   $ 0